Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01E vaccine, seasonal malaria chemoprevention and the combination of vaccination and chemoprevention

Daniel Chandramohan, Alassane Dicko, Issaka Zongo, Issaka Sagara, Matthew Cairns, Irene Kuepfer, Modibo Diarra, Amadou Tapily, Djibrilla Issiaka, Koualy Sanogo, Almahamoudou Mahamar, Frederic Sompougdou, Serge Yerbanga, Ismaila Thera, Paul Milligan, Halidou Tinto, Opokua Ofori-Anyinam, Jean-Bosco Ouedraogo, B Greenwood, Daniel Chandramohan, Alassane Dicko, Issaka Zongo, Issaka Sagara, Matthew Cairns, Irene Kuepfer, Modibo Diarra, Amadou Tapily, Djibrilla Issiaka, Koualy Sanogo, Almahamoudou Mahamar, Frederic Sompougdou, Serge Yerbanga, Ismaila Thera, Paul Milligan, Halidou Tinto, Opokua Ofori-Anyinam, Jean-Bosco Ouedraogo, B Greenwood

Abstract

Introduction: Seasonal malaria chemoprevention (SMC), with sulphadoxine-pyrimethamine plus amodiaquine (SP+AQ) is effective but does not provide complete protection against clinical malaria. The RTS,S/AS01E malaria vaccine provides a high level of protection shortly after vaccination, but this wanes rapidly. Such a vaccine could be an alternative or additive to SMC. This trial aims to determine whether seasonal vaccination with RTS,S/AS01E vaccine could be an alternative to SMC and whether a combination of the two interventions would provide added benefits.

Methods and analysis: This is an individually randomised, double-blind, placebo-controlled trial. 5920 children aged 5-17 months were enrolled in April 2017 in Mali and Burkina Faso. Children in group 1 received three priming doses of RTS,S/AS01E vaccine before the start of the 2017 malaria transmission season and a booster dose at the beginning of two subsequent transmission seasons. In addition, they received SMC SP+AQ placebo on four occasions each year. Children in group 2 received three doses of rabies vaccine in year 1 and hepatitis A vaccine in years 2 and 3 together with four cycles of SMC SP+AQ each year. Children in group 3 received RTS,S/AS01E vaccine and four courses of SMC SP+AQ. Incidence of clinical malaria is determined by case detection at health facilities. Weekly active surveillance for malaria is undertaken in a randomly selected subset of children. The prevalence of malaria is measured in surveys at the end of each transmission season. The primary endpoint is the incidence of clinical malaria confirmed by a positive blood film with a minimum parasite density of 5000 /µL. Primary analysis will be by modified intention to treat defined as children who have received the first dose of the malaria or control vaccine.

Ethics and dissemination: The protocol was approved by the national ethics committees of Mali and Burkina Faso and the London School of Hygiene and Tropical Medicine. The results will be presented to all stakeholders and published in open access journals.

Trial registration number: NCT03143218; Pre-results.

Keywords: epidemiology; immunology; tropical medicine.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study districts in Mali and Burkina Faso.
Figure 2
Figure 2
Study design.

References

    1. Cohen J, Nussenzweig V, Nussenzweig R, et al. . From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin 2010;6:90–6. 10.4161/hv.6.1.9677
    1. RTS,S Clinical Trials Partnership Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015;386:31–45. 10.1016/S0140-6736(15)60721-8
    1. Bojang KA, Milligan PJ, Pinder M, et al. . Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001;358:1927–34. 10.1016/S0140-6736(01)06957-4
    1. BACKGROUND PAPER ON THERTS,S/AS01 MALARIA VACCINE, 2015. Available:
    1. Klein SL, Shann F, Moss WJ, et al. . RTS,S Malaria Vaccine and Increased Mortality in Girls. mBio 2016;7:e00514–6. 10.1128/mBio.00514-16
    1. Wilson AL, IPTc Taskforce . A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS One 2011;6:e16976. 10.1371/journal.pone.0016976
    1. Dicko A, Diallo AI, Tembine I, et al. . Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med 2011;8:1000407. 10.1371/journal.pmed.1000407
    1. Konaté AT, Yaro JB, Ouédraogo AZ, et al. . Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med 2011;8:e1000408. 10.1371/journal.pmed.1000408
    1. Ndiaye JL, Cissé B, EH B, et al. . Safety of seasonal intermittent preventive treatment against malaria with sulfadoxine pyrimethamine + amodiaquine when delivered to children under 10 years of age by district health staff in Senegal. PLoS One. In Press.
    1. Malaria Consortium Seasonal malaria chemoprevention, 2020. Available:
    1. Chandramohan D, Dicko A, Zongo I, et al. . Effect of adding azithromycin to seasonal malaria chemoprevention. N Engl J Med 2019;380:2197–206. 10.1056/NEJMoa1811400
    1. Piaggio G, Elbourne DR, Altman DG, et al. . Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:1152–60. 10.1001/jama.295.10.1152
    1. Leitao J, Chandramohan D, Byass P, et al. . Revising the who verbal autopsy instrument to facilitate routine cause-of-death monitoring. Glob Health Action 2013;6:21518. 10.3402/gha.v6i0.21518
    1. Swysen C, Vekemans J, Bruls M, et al. . Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J 2011;10:e223. 10.1186/1475-2875-10-223
    1. Neafsey DE, Juraska M, Bedford T, et al. . Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N Engl J Med 2015;373:2025–37. 10.1056/NEJMoa1505819
    1. Xu Y, Lam KF, Cheung YB. Estimation of intervention effects using recurrent event time data in the presence of event dependence and a cured fraction. Stat Med 2014.
    1. Cairns M, Cheung YB, Xu Y, et al. . Analysis of preventive interventions for malaria: exploring partial and complete protection and total and primary intervention effects. Am J Epidemiol 2015;181:1008–17. 10.1093/aje/kwv010

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere